AbbVie's Allergan Aesthetics Announces That The U.S. FDA Accepted For Review The SPMA Application For SKINVIVE By JUVÉDERM To Reduce Neck Lines For The Improvement Of Neck Appearance In Adults Over The Age Of 21

• SKINVIVE by JUVÉDERM® is currently approved in the U.S. as the first and only hyaluronic acid microdroplet injectable indicated to improve cheek skin smoothness.
• If approved, SKINVIVE by JUVÉDERM® will be the first hyaluronic acid injectable treatment option aiming to reduce neck lines.
• The application for indication expansion is supported by a clinical study that met all primary and secondary endpoints assessing SKINVIVE by JUVÉDERM® in adults with neck lines seeking improvement in neck appearance.1

IRVINE, Calif., June 30, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced that the U.S. Food and Drug Administration (FDA) accepted for review the supplemental premarket approval (sPMA) application for SKINVIVE by JUVÉDERM® to reduce neck lines for the improvement of neck appearance. SKINVIVE by JUVÉDERM® is currently approved in the U.S. to improve skin smoothness of the cheeks in adults over the age of 21.